Promoting Diversity, Equity, and Inclusion for Psoriatic Diseases

References

1. 1.↵
   Robert Wood Johnson Foundation. Visualizing health equity: one size does not fit all infographic. [Internet. Accessed February 7, 2022]. Available from: https://www.rwjf.org/en/library/infographics/visualizing-health-equity.html
2. 2.↵
   1. Armstrong K

   ; National Association of Colleges and Employers (NACE). What exactly is diversity, equity, and inclusion? [Internet. Accessed February 7, 2022]. Available from: https://community.naceweb.org/blogs/karen-armstrong1/2019/06/25/what-exactly-is-diversity-equity-and-inclusion
3. 3.↵
   1. Armstrong AW,
   2. Mehta MD,
   3. Schupp CW,
   4. Gondo GC,
   5. Bell SJ,
   6. Griffiths CEM

   . Psoriasis prevalence in adults in the United States. JAMA Dermatol 2021;157:940-6.

   OpenUrl
4. 4.↵
   1. Fischer AH,
   2. Shin DB,
   3. Gelfand JM,
   4. Takeshita J

   . Health care utilization for psoriasis in the United States differs by race: an analysis of the 2001-2013 Medical Expenditure Panel Surveys. J Am Acad Dermatol 2018;78:200-3.

   OpenUrl
5. 5.↵
   1. Kurd SK,
   2. Gelfand JM

   . The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003-2004. J Am Acad Dermatol 2009;60:218-24.

   OpenUrlCrossRefPubMed
6. 6.↵
   1. Kerr GS,
   2. Qaiyumi S,
   3. Richards J, et al

   . Psoriasis and psoriatic arthritis in African-American patients--the need to measure disease burden. Clin Rheumatol 2015;34:1753-9.

   OpenUrl
7. 7.↵
   1. Gelfand JM,
   2. Stern RS,
   3. Nijsten T, et al

   . The prevalence of psoriasis in African Americans: results from a population-based study. J Am Acad Dermatol 2005;52:23-6.

   OpenUrlCrossRefPubMed
8. 8.↵
   1. Abrouk M,
   2. Lee K,
   3. Brodsky M, et al

   . Ethnicity affects the presenting severity of psoriasis. J Am Acad Dermatol 2017;77:180-2.

   OpenUrl
9. 9.↵
   1. Shah SK,
   2. Arthur A,
   3. Yang YC,
   4. Stevens S,
   5. Alexis AF

   . A retrospective study to investigate racial and ethnic variations in the treatment of psoriasis with etanercept. J Drugs Dermatol 2011;10:866-72.

   OpenUrlPubMed
10. 10.↵
    1. Takeshita J,
    2. Augustin M,
    3. de Jong E, et al

    . Psoriasis-related quality-of-life differs by race/ethnicity. J Invest Dermatol 2019;139:S148.

    OpenUrl
11. 11.↵
    1. Takeshita J,
    2. Gelfand JM,
    3. Li P, et al

    . Psoriasis in the US Medicare population: prevalence, treatment, and factors associated with biologic use. J Invest Dermatol 2015;135:2955-63.

    OpenUrl
12. 12.↵
    1. Sevagamoorthy A,
    2. Bazen A,
    3. Shin DB,
    4. Barg FK,
    5. Takeshita J

    . Patient race affects dermatologists’ assessments and treatment of psoriasis [abstract]. J Invest Dermatol 2020;140:S97.

    OpenUrl
13. 13.↵
    US Food and Drug Administration. Enhancing the diversity of clinical trial populations - eligibility criteria, enrollment practices, and trial designs guidance for industry. [Internet. Accessed February 7, 2022]. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/enhancing-diversity-clinical-trial-populations-eligibility-criteria-enrollment-practices-and-trial
14. 14.↵
    1. Charrow A,
    2. Xia FD,
    3. Joyce C,
    4. Mostaghimi A

    . Diversity in dermatology clinical trials: a systematic review. JAMA Dermatol 2017;153:193-8.

    OpenUrl
15. 15.↵
    1. Sevagamoorthy A,
    2. Akoh C,
    3. Sockler P,
    4. Takeshita J

    . Racial/ethnic diversity in US clinical trials for acne, atopic dermatitis, and psoriasis [abstract]. J Invest Dermatol 2021;141:S97.

    OpenUrl
16. 16.↵
    Association of American Medical Colleges (AAMC). Diversity in medicine: facts and figures 2019. [Internet. Accessed February 7, 2022]. Available from: https://www.aamc.org/data-reports/workforce/interactive-data/figure-18-percentage-all-active-physicians-race/ethnicity-2018
17. 17.↵
    1. Ly DP

    . Historical trends in the representativeness and incomes of Black physicians, 1900-2018. J Gen Intern Med 2021 Apr 19 (Epub ahead of print).
18. 18.↵
    1. Taylor S,
    2. Kelly AP,
    3. Lim HW,
    4. Serrano AMA

    . Taylor and Kelly’s dermatology for skin of color, 2nd edition. McGraw-Hill Education; 2016.
19. 19.↵
    1. Foster D

    . The Diversity Site Assessment Tool (DSAT), reliability and validity of the industry gold standard for establishing investigator site ranking. Integr J Med Sci 2020;7:266.

    OpenUrl
20. 20.↵
    1. Kremidas J

    . Increasing diversity at investigator sites could increase minority participation in clinical trials. [Internet. Accessed February 7, 2022]. Available from: https://catalyst.phrma.org/increasing-diversity-at-investigator-sites-could-increase-minority-participation-in-clinical-trials